In the United States, the Alzheimer's diagnosis and drugs market is witnessing robust growth, driven by continuous advancements in diagnostic technologies, disease-modifying therapies, biomarker research, and substantial investments in neuroscience. The presence of leading pharmaceutical companies, strong government support through research funding, and favorable regulatory initiatives are...